Antimicrobial peptides and the gut microbiome in inflammatory bowel disease |
| |
| Authors: | John Gubatan Derek R Holman Christopher J Puntasecca Danielle Polevoi Samuel JS Rubin Stephan Rogalla |
| |
| Institution: | John Gubatan, Stephan Rogalla, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Redwood City, CA 94063, United StatesDerek R Holman, Department of Radiology, Molecular Imaging Program at Stanford , Stanford University, Stanford , CA 94305, United StatesChristopher J Puntasecca, Danielle Polevoi, Samuel JS Rubin, Stanford University School of Medicine, Stanford University, Stanford, CA 94063, United States |
| |
| Abstract: | Antimicrobial peptides (AMP) are highly diverse and dynamic molecules that are expressed by specific intestinal epithelial cells, Paneth cells, as well as immune cells in the gastrointestinal (GI) tract. They play critical roles in maintaining tolerance to gut microbiota and protecting against enteric infections. Given that disruptions in tolerance to commensal microbiota and loss of barrier function play major roles in the pathogenesis of inflammatory bowel disease (IBD) and converge on the function of AMP, the significance of AMP as potential biomarkers and novel therapeutic targets in IBD have been increasingly recognized in recent years. In this frontier article, we discuss the function and mechanisms of AMP in the GI tract, examine the interaction of AMP with the gut microbiome, explore the role of AMP in the pathogenesis of IBD, and review translational applications of AMP in patients with IBD. |
| |
| Keywords: | Antimicrobial peptides Inflammatory bowel disease Ulcerative colitis Crohn’s disease Gut microbiome Biomarkers |
|
| 点击此处可从《世界胃肠病学杂志(英文版)》浏览原始摘要信息 |
|
